Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.64 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CASP2 | P42575 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.41 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1527147 | 0.92 | DNM1 (0.72) | DNM1PAOXKDM4EALOX15NAAA | |
| SCHEMBL13236373 | 0.91 | DNM1 (0.67) | DNM1PAOXKDM4EALOX15NAAA | |
| SCHEMBL19115444 | 0.88 | DNM1 (0.59) | DNM1PAOXMAPTKDM4AHIF1A | |
| SCHEMBL23899001 | 0.86 | DNM1 (0.82) | DNM1PAOXKDM4ENAAATSHR | |
| SCHEMBL8773743 | 0.86 | DNM1 (0.76) | DNM1PAOXKDM4EALOX15NAAA | |
| SCHEMBL8411348 | 0.85 | DNM1 (0.64) | DNM1PAOXKDM4ENAAATSHR | |
| SCHEMBL766399 | 0.85 | DNM1 (0.64) | DNM1PAOXCYP2C9CYP2C19KDM4A | |
| SCHEMBL7137887 | 0.84 | DNM1 (0.79) | DNM1PAOXKDM4ENAAATSHR | |
| SCHEMBL6247546 | 0.84 | DNM1 (0.58) | DNM1PAOXKDM4EALOX15TSHR | |
| SCHEMBL16359464 | 0.84 | DNM1 (0.68) | DNM1PAOXKDM4ENAAACASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759357-B2 | Phenylpyrimidine amines as IgE inhibitors | NOVARTIS AG (CH) | 2010-07-20 | — | — | US | disclosed |
| US-7759357-B2 | Phenylpyrimidine amines as IgE inhibitors | NOVARTIS AG (CH) | 2010-07-20 | — | — | US | disclosed |
| US-20070281956-A1 | Phenylpyrimidine amines as IgE inhibitors | NOVARTIS AG (CH) | 2007-12-06 | — | — | US | disclosed |
| US-20070281956-A1 | Phenylpyrimidine amines as IgE inhibitors | NOVARTIS AG (CH) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281956-A1 | Phenylpyrimidine amines as IgE inhibitors | FCER2, SELP, FCGR2A | DNM1 4377/4885PAOX 3252/4885KDM4E 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.